{"output": [["Ardelyx Inc.", "ORG", "Operate_In", "Further Company Coverage", "SECTOR"], ["Ardelyx Inc.", "ORG", "Announce", "Tenapanor for IBS-C", "PRODUCT"], ["Tenapanor for IBS-C", "PRODUCT", "Relate_To", "T3mpo-1 and T3mpo-2 Studies", "EVENT"], ["Tenapanor for IBS-C", "PRODUCT", "Relate_To", "Safety Data", "ECON_INDICATOR"], ["Ardelyx Inc.", "ORG", "Control", "Plans to Submit First NDA", "EVENT"], ["Ardelyx Inc.", "ORG", "Control", "Plans to Submit First NDA", "EVENT", "Relate_To", "U.S. FDA", "ORG/GOV"], ["Ardelyx Inc.", "ORG", "Positive_Impact_On", "H2 2018", "DATE"], ["T3mpo-3", "EVENT", "Showed", "Tenapanor for IBS-C", "PRODUCT", "Is_Member_Of", "Results", "ECON_INDICATOR"], ["T3mpo-3", "EVENT", "Showed", "Tenapanor for IBS-C", "PRODUCT", "Positive_Impact_On", "240 Patients", "PERSON"]], "published": "2018-01-03T13:38:00.000+02:00"}